SK Bioscience to Develop Ebola Vaccine with Overseas Partner for Bundibugyo Strain
Predicted impact: Medium
Partner development deal is about 20% of revenue, but already reported.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.